NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
N-(4-chloro-3-methyl-1,2-oxazol-5-yl)-2-[2-(6-methyl-2H-1,3-benzodioxol-5-yl)acetyl]thiophene-3-sulfonamide
|
|
|
IUPAC Traditional name
|
|
Brand Name
|
|
Synonyms
|
TBC-11251
|
Sitaxsentan
|
Sitaxentan
|
|
|
CAS Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
Data Source
|
Data ID
|
Price
|
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
ALOGPS 2.1
Acid pKa
|
8.386258
|
H Acceptors
|
6
|
H Donor
|
1
|
LogD (pH = 5.5)
|
3.0911784
|
LogD (pH = 7.4)
|
3.0540793
|
Log P
|
3.091686
|
Molar Refractivity
|
105.8045 cm3
|
Polarizability
|
41.36925 Å3
|
Polar Surface Area
|
107.73 Å2
|
Rotatable Bonds
|
5
|
Lipinski's Rule of Five
|
true
|
Log P
|
3.35
|
LOG S
|
-4.4
|
Solubility (Water)
|
1.81e-02 g/l
|
PROPERTIES
PROPERTIES
Bioassay(PubChem)
DETAILS
DETAILS
DrugBank
DrugBank -
DB06268
|
Item |
Information |
Drug Groups
|
approved; investigational |
Indication |
Investigated for use/treatment in pulmonary hypertension, connective tissue diseases, hypertension, and congestive heart failure. |
Pharmacology |
Sitaxentan belongs to a class of drugs known as endothelin receptor antagonists (ERAs). Patients with PAH have elevated levels of endothelin, a potent blood vessel constrictor, in their plasma and lung tissue. Sitaxentan blocks the binding of endothelin to its receptors, thereby negating endothelin's deleterious effects. |
Biotransformation |
Hepatic (CYP2C9- and CYP3A4-mediated) |
Absorption |
70-100% |
Half Life |
10 hours |
Protein Binding |
99% + |
Elimination |
Renal (50 to 60%) Fecal (40 to 50%) |
External Links |
|
|
PATENTS
PATENTS
PubChem Patent
Google Patent